Mechanisms of Alterations in Cardiac Membrane Ca2+ Transport due to Excess Catecholamines

Cardiovascular Drugs and Therapy

Volumn 10, Issue SUPPL. 1, 1996, Pages 231-238

  Dhalla, Ken S ^a   Rupp, Heinz ^a   Beamish, Robert E ^a   Dhalla, Naranjan S ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Cardiac Ca2+ transport; Cardiac membranes; Catecholamine induced cardiotoxicity; Intracellular Ca2+ overload; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM ION; CATECHOLAMINE; ISOPRENALINE;

CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CARDIOTOXICITY; CATECHOLAMINE RELEASE; CONFERENCE PAPER; HEART MITOCHONDRION; HEART MUSCLE FIBER MEMBRANE; LIFESTYLE; PRIORITY JOURNAL; SARCOLEMMA; SARCOPLASMIC RETICULUM; STRESS;

ADRENERGIC BETA-AGONISTS; ANIMALS; BIOLOGICAL TRANSPORT; CALCIUM; CATECHOLAMINES; CELL MEMBRANE; HEART; HUMANS; ISOPROTERENOL; MYOCARDIUM; SARCOLEMMA; SARCOPLASMIC RETICULUM;

EID: 0029973163     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00120492     Document Type: Article

References (24)

1. Rupp H, Dhalla KS, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: Significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994;24(Suppl 1):S16-S24.
2. Rupp H, Jacob R. Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target? Med Hypotheses 1995;44:217-225.
3. Panagia V, Elimban V, Heyliger CE, Tregaskis M, Beamish RE, Dhalla NS. Sarcolemmal alterations during catecholamine induced cardiomyopathy. In: Beamish RE, Panagia V, Dhalla NS, eds. Pathogenesis of Stress-Induced Heart Disease. Boston, Martinus Nijhoff, 1985:121-131.
4. 2+-transport systems. In: Kawai C, Abelman WH, eds. Pathogenesis of Myocarditis and Cardiomyopathy. Tokyo: University of Tokyo Press, 1987:135-147.
5. Ohkubo T, Jacob R, Rupp H. Swimming changes vascular fatty acid composition and prostanoid generation of rats. Am J Physiol 1992;262:R464-R471.
6. Okumura K, Panagia V, Beamish RE, Dhalla NS. Biphasic changes in the sarcolemmal phosphatidylethanolamine N-methylation activity in catecholamine-induced cardiomyopathy. J Mol Cell Cardiol 1987;19:357-366.
7. Dhalla NS, Dzurba A, Pierce GN, Tregaskis MG, Panagia V, Beamish RE. Membrane changes in myocardium during catecholamine-induced pathological hypertrophy. In: Alpert NR, ed. Myocardial Hypertrophy and Failure. New York: Raven Press, 1983:527-534.
8. 2+ exchange in catecholamine-induced cardiomyopathy. Can J Cardiol 1985;1:225-232.
9. Vetter R, Rupp H. CPT-1 inhibition by Etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins. Am J Physiol 1994;267:H2091-H2099.
10. Dhalla NS, Elimban V, Rupp H, Takeda N, Nagano M. Role of calcium in cardiac cell damage and dysfunction. In: Sperelakis N, ed. Physiology and Pathophysiology of the Heart, 3rd ed. Boston: Kluwer Academic Publishers, 1995: 605-623.
11. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease: In: Spitzer JJ, ed. Myocardial Injury. New York: Plenum, 1983:391-401.
12. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985;17:291-306.
13. Dhalla NS, Yates JC, Naimark B, Dhalla KS, Beamish RE, Ostadal B. Cardiotoxicity of catecholamines and related agents. In: Acosta D Jr, ed. Cardiovascular Toxicology, 2nd ed. New York: Raven Press, 1992:239-282.
14. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982;60:1390-1397.
15. Fliegel L, Takeo S, Beamish RE, Dhalla NS. Adrenochrome uptake and subcellular distribution in the isolated perfused rat heart. Can J Cardiol 1985;1:122-127.
16. Taam GM, Takeo S, Ziegelhoffer A, Singal PK, Beamish RE, Dhalla NS. Effect of adrenochrome on adenine nucleotides and mitochondrial oxidative phosphorylation in rat heart. Can J Cardiol 1986;2:88-93.
17. Dhalla KS, Ganguly PK, Rupp H, Beamish RE, Dhalla NS. Measurement of adrenolutin as an oxidation product of catecholamines in plasma. Mol Cell Biochem 1989;87:85-92.
18. Scheulen M, Wollenberg P, Bolt HM, Kappus H, Remmer H. Irreversible binding of DOPA and dopamine metabolites to protein by rat liver microsomes. Biochem Biophys Res Commun 1975;66:1396-1400.
19. Maisch B, Drude L, Hengstenberg C, Hufnagel G, Schönian U, Schwab D. Cytolytic anticardiac membrane antibodies in the pathogenesis of myopericarditis. Postgrad Med J 1992;68:S11-S16.
20. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328: 1450-1456.
21. Ernsberger P, Haxhiu MA, Graff LM, Collins LA, Dreshaj I, Grove DL, et al. A novel mechanism of action for hypertension control: Moxonidine as a selective I1-imidazoline agonist. Cardiovasc Drugs Ther 1994;8(Suppl 1):27-41.
22. Schafers RF, Philipp T. Moxonidine in hypertension treatment - a clinical summary. Cardiovasc Risk Factors 1995; 5(Suppl 1):45-54.
23. Kirch W. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990;30:1088-1095.
24. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5:967-972.